CSPG4 and breast carcinoma: Most recently, ABT-737 and two other BH3 mimetics were tested in combination with a chondroitin sulfate proteoglycan 4 (CSPG4)-targeting immunotoxin in patient-derived melanoma, glioblastoma, and breast cancer cell lines and demonstrated significant synergy.